Glasgow-based @mironidltd, a #biopharmaceutical company, has closed a €39.9 million Series B round to push its lead drug candidate for Autosomal Dominant Polycy...

Glasgow-based @mironidltd, a #biopharmaceutical company, has closed a €39.9 million Series B round to push its lead drug candidate for Autosomal Dominant Polycystic #Kidney #Disease through #clinical development. 🏴󠁧󠁢󠁳󠁣󠁴󠁿 💊 💉

https://t.co/9lFKBnB3nh